Relevant bibliographies by topics / Pregnancy, Cancer, Chemotherapy, Outcome

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Pregnancy, Cancer, Chemotherapy, Outcome'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pregnancy, Cancer, Chemotherapy, Outcome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pregnancy, Cancer, Chemotherapy, Outcome"

1

Walsh, Elaine, Grainne O'Kane, Karen Anne Cadoo, Donna M. Graham, Grzegorz Korpanty, Derek Gerard Power, and Desmond Carney. "Cancer in pregnancy: To treat or not?" Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e12533-e12533. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e12533.

Full text
Abstract:
e12533 Background: Cancer in pregnancy accounts for ~1 in 1,000 pregnancies. Studies show that cytotoxic agents are safe from the second trimester. Long-term follow up has not shown increased malformations or malignancies in children exposed to chemotherapy in utero. There is no evidence of worse outcomes among women diagnosed in pregnancy. Methods: We retrospectively identified women diagnosed with cancer in pregnancy over a 25-year period. Medical records were reviewed for demographics, diagnosis, gestation, timing of treatment and outcomes. We assessed if all cancers need to be treated in pregnancy or if treatment could be safely deferred to allow normal delivery. Results: Twenty-five women were diagnosed with cancer in pregnancy and referred to medical oncology. Of 25 women, 16 (64%) received chemotherapy during pregnancy. These included 13 cases of breast cancer, one Ewing’s sarcoma, one ovarian cancer, and one small cell of cervix. All 16 women received doxorubicin and cyclophosphamide. There were 15 live births and no abnormalities seen in children who received chemotherapy in utero. At a median follow-up of 6 years 11 mothers (69%) are disease free and 4 (25%) have recurrent disease. Of nine mothers who did not receive chemotherapy in pregnancy, seven received chemotherapy immediately post-partum. Six (86%) were diagnosed in early pregnancy (median gestation 13 weeks). There were three cases of Hodgkin lymphoma, two breast cancers, and one ovarian cancer. At a median follow-up of 12 years, all mothers remain disease free. There were no abnormalities seen in these children. Conclusions: We did not identify any adverse outcomes in mothers or infants exposed to chemotherapy during pregnancy. We identified a cohort of patients that do not need immediate treatment during pregnancy. In selected cases, it is safe and appropriate to delay chemotherapy until delivery of the baby. There were no adverse outcomes to mothers due to delayed treatment and no adverse outcomes to babies not exposed to chemotherapy in utero. A multi-disciplinary team is essential to individualize treatment planning. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
2

Ricci, Caterina, Giovanni Scambia, and Rosa De Vincenzo. "Locally Advanced Cervical Cancer in Pregnancy: Overcoming the Challenge. A Case Series and Review of the Literature." International Journal of Gynecologic Cancer 26, no. 8 (October 2016): 1490–96. http://dx.doi.org/10.1097/igc.0000000000000795.

Full text
Abstract:
ObjectiveCervical cancer is the most common gynecological cancer occurring in pregnancy, creating a complex situation both for patient and physician. Neoadjuvant chemotherapy is an innovative way of managing cervical cancer in pregnancy.MethodsIn our paper, we report a retrospective case series of 4 women treated with chemotherapy for invasive cervical cancer during pregnancy in our center over the last 5 years, and we summarize the available literature and guidelines.ResultsAll the cases were locally advanced cervical cancers that received chemotherapy with platinum and/or taxanes. All patients showed a good response to chemotherapy and a radical surgery was performed with no additional morbidities at the cesarean delivery time in 3 of 4 cases. Three of 4 patients are alive and have a good outcome with no recurrence of disease up to date. One patient died because of recurrent disease 2 years after the first-line treatment during pregnancy. All babies are alive and well up to date (maximum follow-up, 63 months).ConclusionsEven if there are no standardized practices in the treatment of cervical cancer in pregnancy, in our opinion, neoadjuvant chemotherapy can be a very useful strategy for patients and physicians facing the challenge.
APA, Harvard, Vancouver, ISO, and other styles
3

Amant, Frederic, Valentina Nekljudova, Charlotte Maggen, Fenja Seither, Patrick Neven, Elyce Cardonick, Sabine Schmatloch, et al. "Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 515. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.515.

Full text
Abstract:
515 Background: Overall a diagnosis of breast cancer during pregnancy (BCP) appears not to impact maternal prognosis if standard treatment is offered. However, caution is warranted as gestational changes in pharmacokinetics with respect to the distribution, metabolism and excretion of drugs may lead to reduced chemotherapy concentration in pregnant patients. This cohort study was designed to focus on the maternal prognosis of BCP patients that receive chemotherapy during pregnancy. Methods: The outcome of BCP patients treated with chemotherapy during pregnancy was compared to non-pregnant breast cancer patients treated with chemotherapy, diagnosed after 2000, excluding postpartum diagnosis and with an age limit of 45 years. The data was registered by two multicentric registries (the International Network of Cancer, Infertility and Pregnancy and the German Breast Cancer Group) that collect both retro-and prospectively breast cancer data. Cox proportional hazards regression was used to compare disease-free (DFS) and overall survival (OS) between both groups, adjusting for age, stage, grade, hormone receptor status, human epidermal growth factor 2 status and histology, weighted by propensity scoring in order to account for the differences in baseline characteristics between pregnant patients and controls. Results: In total, 662 pregnant and 2081 non-pregnant patients, were eligible for analysis. Median age at diagnosis was 34 (range 22-47) years for pregnant and 38 (range 19-45) years for non-pregnant patients. Pregnant patients were more likely to have stage II breast cancer (60.1% vs 56.1%, p = 0.035), grade 3 tumors (74.0% vs 62.2%, p < 0.001), hormone receptor-negative tumors (48.4% vs 34.0%, p < 0.001) or triple-negative breast cancer (38.9% vs 26.9%, p < 0.001). Median follow-up was 66 months. DFS and OS were comparable for pregnant and non-pregnant patients (DFS: HR 1.02, 95%CI 0.82-1.27, p = 0.83; OS: HR 1.08, 95% CI 0.81-1.45, p = 0.59). A subgroup analysis of 339 women that received more than 60% of chemotherapy during pregnancy (cut-off at median) revealed a comparable survival compared to non-pregnant women (DFS: HR 0.81, 95%CI 0.62-1.06, p = 0.13; OS: HR 0.85 95% CI 0.58-1.23, p = 0.39). Conclusions: Pregnancy-induced alternations in chemotherapy concentration do not seem to affect maternal prognosis in breast cancer patients. These results support initiation of chemotherapy for BCP where indicated for oncological reasons.
APA, Harvard, Vancouver, ISO, and other styles
4

Devi, Renuka, Nithya Jagadeesan, and Saritha Kamala Raghavan. "A successful pregnancy outcome in a testicular cancer survivor: case report." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 6, no. 5 (April 27, 2017): 2106. http://dx.doi.org/10.18203/2320-1770.ijrcog20171985.

Full text
Abstract:
Testicular cancer is the most common cancer in young men. We report a successful pregnancy that was achieved by intracytoplasmic sperm injection (ICSI) using cryopreserved semen from a man with testicular cancer. He was treated for left testicular mixed germ cell tumor with left radical orchiectomy followed by chemotherapy. Three years post chemotherapy, the couple had two successive failures of intrauterine insemination (IUI) with cryopreserved semen. The couple then underwent Assisted reproduction with ICSI. Ten oocytes were retrieved following stimulation of which six oocytes fertilized and progressed. She had transfer of two healthy embryos and the remaining four embryos cryopreserved. Singleton pregnancy was achieved and she delivered a healthy girl baby at 38 weeks of gestation. Assisted reproduction with ICSI is a boon to the male patients with cancer and offers them a chance of fathering their own biological offspring.
APA, Harvard, Vancouver, ISO, and other styles
5

Maggen, Charlotte, Mathilde van Gerwen, Kristel Van Calsteren, Tineke Vandenbroucke, and Frédéric Amant. "Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article." International Journal of Gynecologic Cancer 29, no. 2 (January 18, 2019): 404–16. http://dx.doi.org/10.1136/ijgc-2018-000061.

Full text
Abstract:
The diagnosis of cancer during pregnancy imposes a medical-ethical dilemma in weighing the risks of both mother and child. Increasing awareness of the feasibility of chemotherapy during pregnancy results in more pregnant patients receiving treatment for cancer. Information on obstetric and pediatric outcome of these high-risk pregnancies is greatly needed to guide physicians in patient counseling. In this review we present reported evidence for the incidence, diagnostic options, therapeutic management, obstetric risks, and neonatal outcome when cancer treatment is initiated during pregnancy. Decision-making when a cancer is diagnosed in a pregnant patient should be multidisciplinary, always taking the patient’s perspective into account. Cancer treatment during pregnancy is associated with low birth weight and preterm delivery, therefore frequent obstetric follow-up during oncological treatment in a specialized center is mandatory. Short-term clinical, cardiac, and cognitive outcome of children pre-natally exposed to cancer treatment is overall reassuring. Long-term follow-up of children is warranted to define the possible effect of pre-natal cancer treatment on general health, fertility outcome, and the risk of secondary cancers.
APA, Harvard, Vancouver, ISO, and other styles
6

Pariyar, J., B. Shrestha, BC Acharya, KS Sharma, J. Shrestha, S. Shrestha, S. Sundas, and S. Panthee. "Leukaemia with pregnancy managed at B. P. Koirala Memorial Cancer Hospital." Nepalese Journal of Cancer 2, no. 1 (September 30, 2018): 71–74. http://dx.doi.org/10.3126/njc.v2i1.25661.

Full text
Abstract:
Abstract: Leukaemia during pregnancy is rare, occurring approximately one in every 75,000 to 100,000 pregnancies annually. Chemotherapeutic agents may have harmful effects to the developing baby though leukaemia itself rarely harms the baby. There is no evidence that pregnancy accelerates the progression of disease or affects the outcome. However, treatment dilemmas often occur. Aims: To study the clinical presentation, treatment and outcome of leukaemia with pregnancy managed at B. P. Koirala Memorial Cancer Hospital (BPKMCH). Methods: Descriptive study was conducted at BPKMCH. Case records of women with cancer and pregnancy from January 2006 to February 2013 were analyzed regarding their clinical details, treatment, follow-up and feto-maternal outcome. Results: Six women, of 20 to 28 years had leukaemia with pregnancy among which four were chronic myeloid leukaemia (CML), one was acute lymphocytic leukaemia (ALL) and acute myeloid leukaemia (AML) each. All four cases of CML had conceived while on oral Imatinib; the three case diagnosed in the first trimester opted for immediate termination of pregnancy while the fourth one diagnosed at 22 weeks of pregnancy continued pregnancy and delivered at 34 weeks by emergency caesarean section for severe oligohydramnios. The ALL case diagnosed at 26 weeks of pregnancy wanted termination of pregnancy and immediate induction chemotherapy. The AML case diagnosed at 32 weeks of pregnancy desired to undergo induction chemotherapy with pregnancy but she defaulted treatment and had intrauterine fetal death and died due to postpartum haemorrhage. The baby, delivered to a mother exposed to Imatinib throughout pregnancy, till date has normal growth and development. Five mothers are in remission. Conclusions: Leukaemia with pregnancy, more common in younger women is rare and posed treatment challenges. Definitive treatment should be individualized according to the desire of the pregnant woman and should include a multi- disciplinary team. Termination of pregnancy in favour of definitive chemotherapy to mother is better and easier during the first trimester of pregnancy. Because of teratogenic effects of chemotherapy, effective contraception be used during therapy to prevent pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
7

IONESCU, Olivia, and Nicolae BACALBASA. "Gestational breast cancer. Surgical treatment, pregnancy and fetal outcome." Romanian Journal of Medical Practice 12, no. 2 (March 31, 2017): 16–22. http://dx.doi.org/10.37897/rjmp.2017.1.3.

Full text
Abstract:
Background. Gestational breast cancer (GBC) is also known as pregnancy-associated breast cancer and it comprises all the breast cancers (BCs) which are diagnosed either during pregnancy or in the first year after delivery or during the lactation period. At present it has been confirmed that the breast malignancies are the most common forms of cancer in pregnant women with a constant increase in its incidence because of the continuous postpone in childbearing especially in women older than 40 years. However, when diagnosed during the pregnancy, the treatment modalities of the BC are complex and difficult to establish as it must be considered the impact of the treatment both on the child and the course of pregnancy. Purpose. Using an online search on Pubmed, our aim was to make a review of the treatment possibilities of a pregnant woman presenting a breast malignant tumor. We have concentrated our paper on the surgical treatment and the possibility of an oncoplastic reconstruction types, the facts of radiotherapy during pregnancy and the prognosis of the GBC particularly in women who opt to continue the pregnancy. A resume of the epidemiology of GBG is also presented. Method. The following key words have been on Pubmed introduced: ,,breast cancer’’, ,,pregnancy’’, ,,staging”, ,,chemotherapy” and ,,radiotherapy”. As mentioned above, we have tried to select the BC cases diagnosed and treated during pregnancy for which the decision of the patient was to continue the pregnancy in spite of the diagnosis. We further aimed to present the prognosis of the pregnancy-associated BC, namely the pregnancy and fetal outcome, and to investigate if the decision to terminate the pregnancy is associated with a survival benefit. Conclusion. The surgical treatment of pregnancy-associated BC does not differ from that of non-pregnancy BC. Axillary LN-dissection is permitted while the data on the safety of sentinel-LN are still poor. Elective termination of the pregnancy has no impact on the overall survival of the patient.
APA, Harvard, Vancouver, ISO, and other styles
8

Sarantaki, Antigoni, and Kyriaki Perisaki. "Breast Cancer: Treatment Effects on Fertility and Subsequent Pregnancy Outcomes." Medical Science and Discovery 8, no. 8 (August 19, 2021): 442–47. http://dx.doi.org/10.36472/msd.v8i8.587.

Full text
Abstract:
Objective: Breast cancer is the most common cancer type in women of reproductive age. Given that most women postpone childbearing, breast cancer occurrence possibly perplexes their plans for starting a family. The treatment for breast cancer can affect their fertility and have adverse effects on a pregnancy that occurs during that period. The aim of this narrative review is primarily to explore the influence of breast cancer therapy on the ability of a woman diagnosed with breast cancer to gestate. Moreover, to determine the safer timing for childbearing after being treated for breast cancer and investigate the pregnancy outcome when conception is succeeded. Childbearing after treatment for breast cancer is considered safe and pregnancy outcomes are favorable if conception happens 1 year after chemotherapy or at least 2 years after chemotherapy and radiation therapy. Counseling is of great significance and fertility preservation methods should be thoroughly discussed with women diagnosed with breast cancer, even prior to commencement of the treatment
APA, Harvard, Vancouver, ISO, and other styles
9

Ring, Alistair E., Ian E. Smith, Alison Jones, Catherine Shannon, Eleni Galani, and Paul A. Ellis. "Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals." Journal of Clinical Oncology 23, no. 18 (June 20, 2005): 4192–97. http://dx.doi.org/10.1200/jco.2005.03.038.

Full text
Abstract:
Purpose The rare association between breast cancer and pregnancy means that few oncologists gain an expertise in this area. In particular, there are few published data concerning the use of chemotherapy for breast cancer during pregnancy. In this retrospective case series, we describe the experiences of five hospitals in London, United Kingdom, and how they manage this condition. Patients and Methods Retrospective searches were performed at five London hospitals in order to identify women who received chemotherapy for breast cancer while pregnant. Results Twenty-eight women were identified who had received chemotherapy for breast cancer during pregnancy. Twenty-four women received adjuvant or neoadjuvant chemotherapy for early breast cancer, and four women received palliative chemotherapy for metastatic disease. A total of 116 cycles of chemotherapy were administered during pregnancy. Sixteen women were treated with anthracycline-based chemotherapy and 12 received cyclophosphamide, methotrexate, and fluorouracil. All but one of the women were treated after the first trimester. One spontaneous abortion occurred in the woman treated during her first trimester; otherwise, there were no serious adverse consequences for the mothers or neonates. Conclusion These data provide evidence that in terms of peripartum complications and immediate fetal outcome, chemotherapy can be safely administered to women during the second and third trimesters of pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
10

Abdel-Hady, El-Said, Reda Abdel-Hady Hemida, Anas Gamal, Maha El-Zafarany, Eman Toson, and Mohammed Attia El-Bayoumi. "Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy." Archives of Gynecology and Obstetrics 286, no. 2 (March 13, 2012): 283–86. http://dx.doi.org/10.1007/s00404-012-2287-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pregnancy, Cancer, Chemotherapy, Outcome"

1

CAMERONI, IRENE. "Tumore e gravidanza. Diagnosi, trattamento e outcome, l'esperienza della clinica ostetrico ginecologica di Monza." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/19597.

Full text
Abstract:
BACKGROUND The exact incidence of cancer during gestation is yet to be determined but it is estimated that cancer occurs in 1 in 1000 pregnancies. The most common cancers in pregnancy are those with a peak incidence during the woman‘s reproductive period such as cancer of the breast and cervix, lymphoma, leukemia and melanoma. Cancer during pregnancy is a challenge about assistance and therapy, the aim of therapy in pregnancy is to give optimal treatment to the mother without harm to the fetus. After cancer diagnosis there are following problems such as the difficulty to stage it according usual criteria, the need to planner differentiated treatment, the need to delay or modify treatment in order to preserve the fetus, the risk of teratogenic effects of chemotherapy, the risk of fetal prematurity and so on. The aim of this study was to analyze the pregnancy outcome in a group of patients whit diagnosis of several malignancies during pregnancy. METHODS We retrospectively analyzed 34 patients who have been treated during pregnancy or after delivery because of several malignancies. Cancer was diagnosed at the moment of obstetric visit and all the patients were staged according to standard criteria pregnancy permitting. Serial visits were done by Oncologist and Obstetrician at the same time to take the relationship between pregnant state, cancer and therapeutic choices into account. Chemotherapy, when useful, was started in the second trimester. In all cases were done fetal monitoring and prematurity complications prophylaxis at viability age. Gestational age at delivery was established according to disease state and fetal risk of prematurity. Was avoided the neonatal spinal marrow aplasia attending two weeks from last chemotherapy course. Placental histology was studied in all cases about the presence of cancer cell or chemotherapy effect. RESULTS Surgery during pregnancy was performed in 27% of cases. Chemotherapy during pregnancy was given in 48% of cases. There were not cases of preeclampsia or stillbirth. 73% of patients delivered before 37 weeks of gestation, of them 42% delivered before 34 weeks of gestation in order to begin a therapy not indicated in pregnancy. The incidence of cesarean section was 73%. The incidence of neonates small for gestational age was 12%. There were not cases of congenital malformations. There were not cases of metastatic involvement of placenta. The neonatal outcome evaluated within 1 year from birth was good in all cases. The maternal mortality was 33% between 3-5 years after delivery. CONCLUSIONS Our data are in conformity with the Literature about the possibility to continue the pregnancy when cancer diagnosis. The possibility to receive in pregnancy chemotherapy in selected cases as standard of care is the assumption to have the same survival between the patients that interrupt the pregnancy and who not. According to advancement of perinatal care is possible to do delivery early, treating the patient with the therapy controindicated in pregnancy, without important complications after 32 weeks of gestation. All neonates had good outcome and follow-up, however the prematurity (69% advanced stage vs 25% early stage) was conditioned by cancer stage at the moment of diagnosis. In conclusion, the most important thing is to follow these patients into Specialized Hospital, taking care the cancer and the pregnancy at the same time.
APA, Harvard, Vancouver, ISO, and other styles
2

Abdel, Azim Hatem Hamdy. "Breast cancer in young women: impact of pregnancy on biology and outcome." Doctoral thesis, Universite Libre de Bruxelles, 2014. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209357.

Full text
Abstract:
In this work, we found that proliferation-related prognostic gene signatures could aid treatment decision-making independent of age. This is clinically relevant for the younger breast cancer population given the potential long-term side effects of adjuvant systemic chemotherapy and hence the need to identify patients who are less likely to benefit adjuvant chemotherapy. In addition, it was clear that young age at diagnosis adds extra biological complexity, which is independent of differences in breast cancer subtype distribution. This includes enrichment with known breast cancer targets like RANKL. Whilst these results require further validation, either experimentally or in other clinical data sets, it suggests that separate therapeutic approaches may need to be specifically designed in order to improve outcomes for breast cancer arising in young women. In this regard, and based on our results and supportive evidence from other studies, we initiated a proof-of-concept prospective phase II neoadjuvant study investigating the role of denosumab, a RANKL inhibitor on modulating tumor biology in young premenopausal breast cancer patients.

We found that diagnosis during pregnancy does not significantly influence the classic pathological features or the prevalence of breast cancer subtypes. We also did not find obvious differences in the distribution of PIK3CA mutations. However, we found that tumors diagnosed during pregnancy have activated serotonin receptor signaling and high expression of potential breast cancer targets; of particular interest IGF1, and PDL1. Such differences appeared to be reflected in the normal pregnant breast underscoring the potential role of the pregnant breast microenvironment on the tumor transcriptome. We were not able to associate these genes with prognosis, which could be partly due to lack of statistical power. Of note, we cannot confirm whether any of these aberrations are key drivers of the biology of tumors diagnosed during pregnancy. Nevertheless, this remains the first study to look into the biology of this relatively rare disease and hence we believe it would serve as a very valuable resource for future research in this field. We are planning to perform targeted gene sequencing to further refine our understanding of the potential effect of pregnancy on the biology of these tumors.

In the last part of this work addressing the safety of pregnancy following breast cancer diagnosis, we identified that available studies suffered major limitations related to study design including selection bias and lack of information on patients with history of an ER-positive disease. This has resulted in advising against pregnancy in women with prior history of breast cancer. Our subsequent study has robustly addressed most of the limitations in older studies and clearly showed that pregnancy following breast cancer is safe even in women with a history of ER-positive disease. Hence, this study would provide a very important resource for the oncology community, which would aid adequate fertility counseling for young breast cancer survivors. This work is currently serving as the basis for a new prospective study by the IBCSG to test the safety of early interruption of tamoxifen in young women with early breast cancer seeking subsequent pregnancy.


Doctorat en Sciences biomédicales et pharmaceutiques
info:eu-repo/semantics/nonPublished

APA, Harvard, Vancouver, ISO, and other styles
3

ANDO, YUICHI, AKIHIRO NAWA, MASAKI SAWADA, KOICHI KITAGAWA, MIHOKO SUGISHITA, TOMOYA SHIMOKATA, MEGUMI INADA, et al. "EXTRAVASATION OF PEGYLATED-LIPOSOMAL DOXORUBICIN: FAVORABLE OUTCOME AFTER IMMEDIATE SUBCUTANEOUS ADMINISTRATION OF CORTICOSTEROIDS." Nagoya University School of Medicine, 2012. http://hdl.handle.net/2237/16037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

SUARDI, ELISA. "HIV-ASSOCIATED CANCERS: ROLE OF IMMUNE PARAMETERS AND RELATION WITH THE OUTCOME OF CHEMOTHERAPY." Doctoral thesis, Università degli Studi di Milano, 2019. http://hdl.handle.net/2434/628815.

Full text
Abstract:
Background: HIV positive patients present a higher risk of cancer compared to the HIV-negative population. Three tumors, namely Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL) and invasive cervical cancer (ICC) occurs with particularly high incidence in HIV-positive patients, and have been classified as AIDS-defining malignancies (ADMs). However, a risk excess is observed for both ADMs and non-AIDS defining malignancies (NADMs). Beside co-infection with oncogenic virus, the pathogenic pathways underlying the development of infection-related and non infection-related cancer in PLWH are sustained by a complex network of interactions between various components of the immune system, with cytokines and other pro-inflammatory agents mediating those interactions. However, these mechanisms have not been fully characterized. Aim: To shed light on this topic, we conducted 3 studies with the following aims: - Natural Killer cell populations in HIV associated lymphoma: Natural Killer (NK, CD56+) cells exert anti-cancer and anti-viral actions and their number and function is impaired during HIV infection. In HIV-negative patients with Hodgkin Lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL), NK cell constitute a higher percentage of circulating lymphocytes and are associated with a better outcome. We aimed to evaluate the NK cell population in HIV-associated lymphomas. - Sex-based differences in factors associated with HPV infection and intraepithelial lesions in a cohort of HIV-positive patients: We aimed to assess the factors associated with HPV infection and with squamous intraepithelial lesions (SILs) in a cohort of HIV-positive patients with focus on gender differences, and possible factors linked with the capability to clear HPV infection, thus influencing the progression of SILs towards cancer. - Association of immune activation markers and CD4/CD8 ratio with the development of virus related and non-virus related cancers in HIV-positive patients: High levels of peripheral T-cells immune activation and low CD4/CD8 ratio in HIV-positive patients have been associated with comorbidities, increased risk of serious events and deaths, despite effective highly active antiretroviral therapy (HAART). Thus, we aimed to assess the association of peripheral immune activation markers (CD8+CD38+ T-lymphocytes) and CD4/CD8 ratio with the onset of infection-related and non-infection related cancers in a cohort of HIV-positive patients virological suppression. We further investigated possible association of CD8+CD38+ T-cells and CD4/CD8 ratio with overall survival of HIV-positive patients with virus-related cancer. Results: Association of immune activation markers and e CD4/CD8 ratio with the development of virus related and non-virus related cancer in HIV-positive patients: We collected clinico-pathologic and treatment data from a prospective series of HIV-positive patients with virus related and non-virus related cancers. We enrolled 140 HIV-positive patients, 115 with virus-related cancer and 25 with non-virus related cancers. We evaluated the association of CD4/CD8 ratio and CD8+CD38+ percentage at the time of first evaluation at our centre with the onset of virus ad non-virus related cancers in uni- and multivariable analyses, in relationship to other HIV-related criteria (CD4+ current and nadir, HIV-RNA, length of HIV infection, cART). Patients with virus-related cancer were more frequently males (p=0.002) and men who have sex with men (MSM) (p=0.003) compared to patients with non-virus related cancers. Further, at the time of cancer diagnosis, patients with virus-related disease were younger (p<0.0001), with a shorter time from HIV-diagnosis (p=0.04)and more frequently naïve to HAART (p=0.009); from an immunological perspective, pre-diagnostic levels of CD8+CD38+ T-cells were higher (p=0.05) and CD4/CD8 ratio was lower (p=0.01) in patients with virus related compared with non-virus related cancer. Natural Killer cell populations in HIV associated lymphoma: Clinical characteristics at lymphoma diagnosis have been prospectively collected at the National Centre for HIV Malignancy at Chelsea & Westminster Hospital, London, since 1986. We reviewed data of 615 HIV-positive patients including 360 lymphomas with full lymphocyte subset analysis at lymphoma diagnosis. The percentage of NK cells was significantly higher in patients with HL (median 9%) than in DLBCL (6%) and other NHL subtypes (p=0.009). The total NK cell count was significantly higher in patients with undetectable HIV-RNA(p<0.0001) but only weakly correlated with CD4 cell count (PearsonsR2 =0.11). For 156 patients with DLBCL, the 5-year OS was 64% (95%CI 56-72%) and in univariate analysis neither total NK-cell population (log rank p=0.14) not NK-cell % (log rank p=0.84) were prognostic variables for OS. In multivariate Cox model the only variable associated with OS was the International Prognostic Index (IPI) (log rank p<0.001). In conclusion, the percentage of NK-cells was reduced in HIV-associated NHL, in contrast with previous reports in HIV-negative patients, and this could contribute to lymphoma development in these patients. The NK-cell population was strongly influenced by effective ARV therapy but only marginally associated with CD4 counts. Nevertheless, NK-cell populations were not predictive of outcome in DLBCL. Sex-based differences in factors associated with HPV infection and intraepithelial lesions in a cohort of HIV-positive patients:We enrolled 472 patients. Anal/cervical brushing samples were collected for HPV-PCR detection/genotyping and cytologic abnormalities at baseline and follow-up visits. Viro-immunological data were recorded at the time of brushing. HPV infection(p<0.001), SIL (p<0.001), HPV persistence (p<0.001) and SIL progression (p=0.018) were all associated with male sex. Among females, HPV was associated with higher HIV-RNA (p=0.002) and SIL was independently associated with lower CD4+ count (AOR: 0.998; 95%CI: 0.997-1). In the males group, HPV was associated with MSM (AOR: 3.801, 95% CI: 1.82-7.95) while AIDS diagnosis (AOR: 0.387 95% CI:0.176-0.851) and older HIV infection (AOR: 0.996 95% CI:0.992-0.999) were negatively associated with HPV infection; males with SIL were younger (AOR 0.973, 95% CI 0.95-0,997), more MSMs (p=0.04) and with higher levels of immune-activation (CD38+CD8+%) (p=0.013) compared to SIL-negative males. In conclusion, the natural history of HPV and SIL is largely influenced by risky behaviors and immune-activation in males, particularly in recently HIV-infected patients, while it appears to be driven by immune-suppression in women. Given the high incidence of HPV infection in both men and women, we suggest that vaccination has to be strongly recommended to all HIV independently form the age and gender.
APA, Harvard, Vancouver, ISO, and other styles
5

Carser, J. C. "The role of BRCA1 as a marker of clinical outcome following chemotherapy in sporadic ovarian cancer." Thesis, Queen's University Belfast, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.517246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Grimison, Peter S. "Improving decision-making deriving patient-valued utilities from a disease-specific quality of life questionnaire for evaluating clinical trials /." Connect to full text, 2009. http://hdl.handle.net/2123/5512.

Full text
Abstract:
Thesis (Ph. D.)--University of Sydney, 2009.
Title from title screen (viewed Nov. 3, 2009) Includes tables and questionnaires. Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the School of Public Health, Faculty of Medicine. Includes bibliography. Also available in print form.
APA, Harvard, Vancouver, ISO, and other styles
7

Kerrigan, Matthew Charles. "Treatment patterns, costs and outcomes of systemic chemotherapy, adjuvant intravesical therapy, and surveillance for urothelial bladder cancer /." Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/7949.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

CIRIELLO, ELENA. "Tumore della mammella in gravidanza: fattori di prognosi e risultati clinici in uno studio caso-controllo." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/20079.

Full text
Abstract:
PURPOSE: Pregnancy-associated breast cancer (PABC) is one of the most common malignancies during pregnancy (one in 3,000 pregnancies); up to 3% of breast cancers are diagnosed in pregnancy. Our objective is to verify if women with pregnancy-associated breast cancer (PABC) have poorer outcome than nonpregnant women with breast cancer. METHODS: We register in a Cancer and Pregnancy Registry the clinical course, treatment, and disease outcome of nonpregnant women with breast cancer and of women with PABC. In a retrospective control study (2:1) we compared the women with PABC (65 cases) with nonpregnant women with breast cancer (130 cases) matched for age at diagnosis, stage of disease and year of surgery. RESULTS: Of 65 cases diagnosed, 45 was early cancer and 20 was locally advanced or metastatic cancer. The pregnancy ended in a spontaneus miscarriage in 3 patients (5%), and 15 (23%) pregnancy were interrupted. The mean age at diagnosis was 36 ± 4.2 years. Treatment was started during pregnancy in 32 (49%) patients and after delivery in 33 (51%) patients. Of 65 cases, 49 (75%) women received chemotherapy, 52 (80%) women received radiotherapy and 46 (71%) women were diagnosed with an estrogen/progesterone receptors-positve tumor. The mean gestational age at delivery was 35.4 ± 2.1 weeks. Eleven women (17%) are deceased and 21 (32%) progressed with a median follow-up of 48 months. There are no difference between cases and control in term of biological features of cancer and treatment. CONCLUSIONS: The treatment of breast cancer in pregnancy should be executed by experienced specialists in a multidisciplinary setting and should adhere as closely as possible to standard protocols. As more women postpone child bearing until later in life, it is expected that PABC will become increasingly more common. The prognosis in pregnant women with breast cancer is worse than in nonpregnant women.
APA, Harvard, Vancouver, ISO, and other styles
9

Brisbois, Maryellen D. "Chemotherapy-Induced Premature Menopause Among Latina Women With Breast Cancer: An Interpretive Description: A Dissertation." eScholarship@UMMS, 2013. https://escholarship.umassmed.edu/gsn_diss/29.

Full text
Abstract:
The description and interpretation of Latinas’ experience with chemotherapyinduced premature menopause from breast cancer treatment were explored in this study, which utilized an interpretive descriptive method from a feminist lens, and Knobf’s (1998, 2002) “Carrying on” theory. The specific aims of the study and the interview questions were guided by the state of the science literature. Overall, the impact of physiological effects, psychosocial effects, barriers, influencing factors that made their experience easier or harder, and how participants adjusted to a cancer diagnosis, treatment course, and menopause transition were described as bigger than the menopause experience alone. Participants also described a period of uncertainty or “ever-changing landscape” that began at the time of diagnosis and continued through survivorship. The impact of information, access to healthcare, acculturation levels, support, and a sense of control were elucidated as important factors in “working through” the experience. A range of collateral data sources were employed. Study limitations and future implications for practice, research, and health policy were demarcated.
APA, Harvard, Vancouver, ISO, and other styles
10

Byström, Per. "Colorectal cancer treatment and early response evaluation how do we best evaluate treatment response? /." Stockholm, 2010. http://diss.kib.ki.se/2010/978-91-7409-766-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pregnancy, Cancer, Chemotherapy, Outcome"

1

(Editor), Anthony F. Shields, and Pat Price (Editor), eds. In Vivo Imaging of Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Price, Pat, and Anthony F. Shields. In Vivo Imaging of Cancer Therapy. Humana Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Amen Sibtain. Colorectal cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0015_update_001.

Full text
Abstract:
Breast cancer reviews the epidemiology and aetiology of this malignancy, with particular attention to the genetics underlying familial breast cancer, its pathology along with its receptors, oestrogen receptor (ER), the growth factor receptor HER2, and epidermal growth factor receptor (EGFR), and the bearing these have on treatment and prognosis. The benefits of breast cancer screening in the population and families at higher risk are discussed. Presenting symptoms and signs are followed by investigation including examination, bilateral mammography, and core biopsy of suspicious lesions. Management of non-invasive in situ disease is considered. Invasive breast cancer is staged according to TNM guidelines. Early breast cancer is defined, managed frequently by breast conserving surgery and sentinel node biopsy from the axilla. A positive sentinel node biopsy requires clearance of the axilla. Larger lesions may require mastectomy. Breast radiotherapy is indicated after breast conserving surgery. Following surgery, the risk of systemic micrometastatic disease is estimated from the primary size, lymph node spread, and tumour grade. Adjuvant chemotherapy improves treatment outcome in all but very good prognosis premenopausal breast cancer, and intermediate or poor prognosis postmenopausal breast cancer. This is combined with trastuzumab in HER2 positive disease. Adjuvant endocrine therapy is recommended for all ER positive breast cancer, tamoxifen in premenopausal, aromatase inhibitors in postmenopausal women. Neoadjuvant chemotherapy may be used in large operable breast cancers to facilitate breast conserving surgery. Locally advanced breast cancer is defined, its high risk of metastatic disease requiring full staging before treatment. Systemic therapy is often best first treatment, according to receptor profile. Metastatic breast cancer although incurable can be controlled for years using endocrine therapy, chemotherapy, trastuzumab, palliative radiotherapy, and bisphosphonates as appropriate. Male breast cancer is uncommon, but management similar.
APA, Harvard, Vancouver, ISO, and other styles
4

Roques, Tom. Oncological management of head and neck cancer III. Edited by John Phillips and Sally Erskine. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834281.003.0053.

Full text
Abstract:
This chapter discusses Pignon, le Maître, Maillard, and Bourhis’s paper on meta-analysis of chemotherapy in head and neck cancer including the design of the study (outcome measures, results, conclusions, and a critique).
APA, Harvard, Vancouver, ISO, and other styles
5

Cutter, David, and Martin Scott-Brown. Treatment of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0325.

Full text
Abstract:
The variety of conditions that are considered to be ‘cancer’ is extremely wide, with marked variation in the management approach from disease to disease. A common feature in the management of malignant conditions, however, is the involvement of a wide range of medical professionals at different stages of the patient pathway. This commonly includes physicians, surgeons, radiologists, pathologists, medical oncologists, radiation oncologists, and specialist nurses, as well as a plethora of other allied disciplines. As such, a practice that has been widely adopted is to work as a multidisciplinary team (MDT), with regular meetings to decide the appropriate treatment for each patient with a cancer diagnosis, on an individual and case-by-case basis. The main treatment modalities for the treatment of cancer are surgery, radiotherapy, and chemotherapy. While these are often combined to form a multimodality therapy, they are all, in isolation, potentially radical (curative) therapies for certain conditions. For example, surgery (in the case of a Stage I colon adenocarcinoma), radiotherapy (in the case of early laryngeal squamous cell carcinoma), and chemotherapy (in the case of acute lymphoblastic leukaemia) are all curative as single-modality treatments. It is commonly the case, however, for a patient to require more than one mode of therapy to achieve the best outcome, for example a combination of surgery, chemotherapy, and radiotherapy for early breast cancer. It can also be the case that two or more different management strategies are thought to give equivalent oncological results, for example surgery or radiotherapy for early prostate cancer. In this situation, the MDT and the patient need to decide on the ‘best’ management plan for the individual, based on their personal and professional opinions and on the differing toxicity profiles of the alternate treatments.
APA, Harvard, Vancouver, ISO, and other styles
6

Zehnder, Pascal, and George N. Thalmann. Muscle-invasive bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0078.

Full text
Abstract:
In the United Kingdom, >4,000 people die of bladder cancer every year. This reflects around one-third of affected patients and occurs in those with primary metastatic disease, with invasion at presentation, and in persons whose tumour progresses to invasion from non-invasive disease. The outcome from invasive cancers has not dramatically altered over the last 30 years, due to a lack of screening programmes, a lack of advances in treatment, and the fact that many patients present with tumours at an advanced stage. Around 50% of patients with invasive disease die from bladder cancer despite radical treatment, suggesting the disease is metastatic at presentation. Cure is rarely possible in patients with locally advanced tumours and lymph node metastases. Therapeutic options include systemic chemotherapy and salvage radical treatment for responders or palliation. Following radical cystectomy for cancer, patients require lifelong follow-up for both oncologic and functional reasons.
APA, Harvard, Vancouver, ISO, and other styles
7

Innominato, Pasquale F., and David Spiegel. Circadian rhythms, sleep, and anti-cancer treatments. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198778240.003.0016.

Full text
Abstract:
The circadian timing system temporally regulates biological functions relevant for psycho-physical wellbeing, spanning all the systems related to health. Hence, disruption of circadian rhythms, along with sleep cycles, is associated with the development of several diseases, including cancer. Moreover, altered circadian and sleep functions negatively impact on cancer patients’ quality of life and survival, above and beyond known determinants of outcome. This alteration can occur as a consequence of cancer, but also of anti-cancer treatments. Indeed, circadian rhythms govern also the ability of detoxifying chemotherapy agents across the 24 hours. Hence, adapting chemotherapy delivery to the molecular oscillations in relevant drug pathways can decrease toxicity to healthy cells, while increasing the number of cancer cells killing. This chronomodulated chemotherapy approach, together with the maintenance of proper circadian function throughtout the whole disease challenge, would finally result in safer and more active anticancer treatments, and in patients experiencing better quality and quantity of life.
APA, Harvard, Vancouver, ISO, and other styles
8

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Full text
Abstract:
The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.
APA, Harvard, Vancouver, ISO, and other styles
9

Ohkawa, Reiko. Psycho-oncology: the sexuality of women and cancer. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198749547.003.0011.

Full text
Abstract:
Female patients undergoing treatment for cancer often experience significant changes in their sexuality due to the disease and its treatment. Sexuality relates to the sexual habits and desires of each individual. It varies according to age-related sexual needs. Many women with cancer consider their sexuality an important aspect of their lives. Yet, they may refrain from sex or enjoy it less following treatment, whether it be surgical or by irradiation, and accompanied by adjunctive chemotherapy or hormonal therapy. Chapter 11 discusses these issues, with a vignette illustrating the impact of an unexpected diagnosis of cancer. Multiple studies have examined sexual dysfunction following treatment of gynaecological cancers, including breast cancer, and several proposed solutions are available. However, the information has not been implemented by many health providers, and patients often experience anxiety and embarrassment when planning to discuss sexuality. The patients may be concerned that their sexual habits might interfere with the treatment outcome, and cause a recurrence of cancer. Reproductive dysfunction is only one of the manifold problems in the female undergoing cancer therapy. It can lead to infertility but certain treatment methods could help retain fertility. Ethical concerns pertaining to the preservation, and use of germ cells, need to be addressed. Ideally, a team of healthcare providers should handle sexual rehabilitation of the cancer survivor based on the patient's history. Unfamiliarity with such matters makes many medical professionals hesitant in discussing their patients' sexuality. The PLISSIT model can help initiate the assessment of sexual dysfunction in these patients.
APA, Harvard, Vancouver, ISO, and other styles
10

O’Neal, M. Angela. What Imaging Test Do I Order? Edited by Angela O’Neal. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190609917.003.0012.

Full text
Abstract:
The case illustrates how to approach imaging in pregnancy. Some basic principles of radiation exposure are reviewed. The effects of radiation are divided into either deterministic, dose-related, or stochastic, where exposure determines the probability of an outcome. Deterministic effects have a threshold below which the effect does not occur. The threshold may be small and may vary from person to person; whereas stochastic effects occur by chance and may occur without a threshold level. Cancer caused by radiation is an example of a stochastic effect. The overall safety of magnetic resonance imaging is discussed. Determining which imaging modality to order depends on the acuity of the situation and the information needed to know in order to adequately treat the mother.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pregnancy, Cancer, Chemotherapy, Outcome"

1

Sanyal, Mrinal K. "Adverse Reproductive Outcome Potential of Cancer Therapies During Pregnancy." In Cancer and Pregnancy, 174–89. London: Springer London, 2001. http://dx.doi.org/10.1007/978-1-4471-0707-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Glimelius, Bengt, and Peter Nygren. "Will Adjuvant Chemotherapy Improve Outcome After Preoperative Chemoradiation?" In Multidisciplinary Management of Rectal Cancer, 217–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-25005-7_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Malakar, Abhishek, Anshul Grover, and Ritu Khatuja. "Review: Clinical Trials Outcome for Chemotherapy in Endometrial Cancer." In Recent Advances in Endometrial Cancer, 161–78. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-5317-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Neves, José, Almeida Dias, Cristiana Silva, Diana Ferreira, Luís Costa, Filipa Ferraz, Victor Alves, João Neves, Jorge Ribeiro, and Henrique Vicente. "Prediction of Neoadjuvant Chemotherapy Outcome in Breast Cancer Patients." In Lecture Notes in Electrical Engineering, 324–32. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21507-1_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ullah, Mohammad Fahad, Showket H. Bhat, and Faisel M. Abuduhier. "Dietary Factors May Influence the Clinical Outcome of Chemotherapy in Cancer Multidrug Resistance." In Critical Dietary Factors in Cancer Chemoprevention, 307–19. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-21461-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nygren, Peter, and Bengt Glimelius. "Will Adjuvant Chemotherapy Improve Outcome After Preoperative (Chemo) Radiotherapy? Still More Passion than Evidence." In Multidisciplinary Management of Rectal Cancer, 313–23. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-43217-5_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fujimoto, S., M. Takahashi, R. D. Shrestha, M. Kokubun, K. Kobayashi, S. Kiuchi, and C. Konno. "Clinical outcome of intraperitoneal hyperthermo-chemotherapy for patients with refractory gastric cancer." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 209–16. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Holmberg, Leona A., Katherine A. Guthrie, and Brenda M. Sandmaier. "Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine." In ACS Symposium Series, 197–215. Washington, DC: American Chemical Society, 2008. http://dx.doi.org/10.1021/bk-2008-0990.ch009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Huang, Shao Hui, Avinash Pilar, Jishi Li, Zhiyuan Xu, and Brian O’Sullivan. "Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma." In Critical Issues in Head and Neck Oncology, 119–37. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_9.

Full text
Abstract:
AbstractThe majority of head and neck squamous cell carcinoma (HNSCC) is now classified into two major types: HPV-mediated [HPV(+)] and HPV-negative [HPV(−)]. Within this paradigm, the 8th edition TNM staging system effected modification about what is considered “locally-advanced” HNSCC. Two phase-III trials (RTOG 1016 and De-ESCALATE HPV) disappointingly showed that cetuximab is not as effective in HPV(+) oropharyngeal cancer (OPC) compared to cisplatin with radiotherapy. The recent NRG HN002 de-escalation trial demonstrated the presence of outcome heterogeneity within “low-risk” HPV(+) OPC, some of which continue to benefit from cisplatin combined with reduced-dose radiotherapy. Moreover, distant metastasis (DM) has consolidated its position as the leading cause of death in HPV(+) OPC and strategies to mitigate it are necessary. Unanswered questions and ongoing-emerging concepts exist in both HPV(+) and HPV– diseases. These include understanding the importance of risk under the rubric of extranodal extension (ENE), including degrees of pathological ENE (pENE), and emerging knowledge about radiologic ENE (rENE). Strategies addressing modification of biological phenomena have become paramount and includes hypoxia modification (such as smoking cessation). In addition, contemporary evidence suggests that immunotherapy improves survival in recurrent/metastatic settings, and it is now also being explored in primary disease presentations in combination with (chemo-)radiotherapy. Induction chemotherapy achieves DM reduction in nasopharyngeal cancer but has only been explored minimally in HPV(+) OPC. Evidence that loco-regional management can be de-intensified following a favorable response to induction treatment would provide an attractive option for HPV(+) OPSCC patients while also addressing risk of developing distant disease.
APA, Harvard, Vancouver, ISO, and other styles
10

Zemlickis, D., M. Lishner, P. Degendorfer, T. Panzarella, S. B. Sutcliffe, and G. Koren. "Fetal outcome following in utero exposure to cancer chemotherapy: the Toronto Study." In Cancer in Pregnancy, 181–88. Cambridge University Press, 1996. http://dx.doi.org/10.1017/cbo9780511663512.019.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pregnancy, Cancer, Chemotherapy, Outcome"

1

Chaudhary, Sushila. "Successful pregnancy outcome in recurrent ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685320.

Full text
Abstract:
Incidences of ovarian cancer in pregnancy are increasing nowadays due to routine use of ultrasonography in first trimester and postponement of childbirth to an older age. Reported incidence of ovarian tumor in pregnancy is 1:1000 among them3.6% are malignant. We report a case of recurrent ovarian tumor with successful pregnancy outcome. She was a 26 yr old primi had ovarian cancer recurrence 2 year after primary surgery. In present pregnancy she was given chemotherapy with two doses of carboplatin, and had viable baby at 34 weeks of pregnancy. At present mother and baby are doing well and on regular follow-up at radiotherapy departments.
APA, Harvard, Vancouver, ISO, and other styles
2

Yoshimura, Adriana Akemi, André Mattar, Bruna S. Mota, Carlos Elias Fristachi, Eduardo Carvalho Pessoa, Felipe Eduardo Andrade, Giuliano Tosello, et al. "A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: III – THERAPEUTIC ASPECTS AND ONCOLOGICAL OUTCOMES." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1091.

Full text
Abstract:
Introduction: We have originally introduced the concept of ultra young women (UYW), defined as age ≤30 years old. It is generally accepted that UYW patients with breast cancer (BC) share some unfavorable outcomes and the patients are faced with family and professional problems, and unique quality of life issues, including loss of fertility, contraception, pregnancy, sexuality, cancer during pregnancy, body image and emotional distress, that complicate treatment decisions making. Objectives: Study the type of surgical and systemic treatment and oncologic outcomes in UYW with BC. Methods: We conducted a multicentric, observational, retrospective study of consecutive BC UYW patients. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo participated. The following data were recorded: type of surgery, chemotherapy, endocrinetherapy, and radiotherapy. Individual oncologic evolution was analyzed and the patients were classified as alive without disease (AWD), alive with local recurrence (ALR), alive with systemic recurrence (ASR), died from BC (DBC) or died from another cause (DOC). The research protocol was approved by the Ethics Committee of all Collaborative Centers. Results: Sixteen percent of UYW with BC underwent mastectomies, 10% nipple-sparing mastectomies and 16% breast conservative surgeries. About 50% had immediated breast reconstruction. Sentinel node biopsy was performed in 24%. 18% had more than four compromised LNs, 8% with extracapsular leak. 37% received adjuvant or palliative chemotherapy. 61% were submitted to irradiation. 54% had adjuvant hormonetherapy. The mean time of follow-up was 41.5 months (1.5-207). It was observed that 59% were AWD, 1% ALR, 7% ASR and 23% DBC, unfortunately standing out the elevated contingent of BC-related deaths. Conclusions: BC therapy in UYW were tailored according to individual characteristics, but the oncological outcomes in this age range at the moment could be considered unfavorable.
APA, Harvard, Vancouver, ISO, and other styles
3

Cardonick, EH, and D. Gilmandyr. "Abstract P5-10-21: Maternal and Neonatal Outcomes of Dose Dense Chemotherapy for Breast Cancer in Pregnancy." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p5-10-21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Loreto, Eugenia DI, Alessandra Familiari, Veronica Accurti, Tiziana Boggini, Carlotta Castellani, Gianpiero Polverino, Julia Bewart, Monica Fumagalli, Fedro Alessandro Peccatori, and Giovanna Scarfone. "389 Chemotherapy during pregnancy and neonatal outcome: a retrospective analysis on 47 patients." In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.85.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Berger, N., K. Fitzpatrick, and P. Klein. "Abstract P6-16-10: Is pregnancy testing during chemotherapy standardized?" In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-16-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cordoba, O., M. Sabadell, I. Rubio, T. Cortadellas, and J. Xercavins. "Pregnancy after Breast Cancer in Young Patients Does Not Worsen the Outcome of Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-2062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lopez, A., J. Rodríguez, E. Estrada, C. Chavez, C. Amaro, A. Aragona, C. De Padua, et al. "309 Neo-adjuvant chemotherapy for cervical cancer during pregnancy: a retrospective case series." In IGCS 2020 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-igcs.265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Crown, Angelena, Damian McCartan, Michael Curry, Maya Feldman, Sujata Patil, Sabrina Kamer, Shari B. Goldfarb, and Mary Gemignani. "Abstract PS1-18: Pregnancy-associated breast cancer: Does timing of presentation affect outcome?" In Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ps1-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hank, T., U. Klaiber, U. Hinz, T. Hackert, M. Büchler, and O. Strobel. "Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer." In Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733586.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hank, T., U. Klaiber, U. Hinz, T. Hackert, M. Büchler, and O. Strobel. "Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer." In Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733586.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pregnancy, Cancer, Chemotherapy, Outcome"

1

Kang, Jing, Jun Zhang, Zongsheng Tian, Ye Xu, Jiangbi Li, and Mingxina Li. The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0156.

Full text
Abstract:
Review question / Objective: Population: histologically confirmed advanced NSCLC patients; Intervention: received immune-checkpoint inhibitor plus chemotherapy; Comparison:received chemotherapy; Outcome: reported OS, PFS, ORR and TRAEs; Study design: RCT. Condition being studied: Lung cancer is the primary cause of cancer-related deaths, with an estimated 2.20 million new cases and 1.79 million deaths every year, and 85% of all primary lung cancers are non-small cell lung cancer. Eligibility criteria: Studies were considered eligible if they met the following criteria: (1) being an randomized controlled trial published in English, (2) histologically confirmed advanced NSCLC patients, (3) reported OS, PFS, ORR and TRAEs, (4) the intervention group received immune-checkpoint inhibitor plus chemotherapy, while the control group received chemotherapy, (5) When numerous papers reporting the same trial were found, the most current or most complete publications were chosen. The following were the exclusion criteria: (1) duplicate articles, (2) reviews, meta-analyses, case reports, editorials and letters, (3) molecular biology or animal research, (4) retrospective or prospective observational cohort studies.
APA, Harvard, Vancouver, ISO, and other styles
2

Guo, Jing, Yu han Chen, Chun xiao Li, Xiao Ling, Panpan Wang, Yuqing Yang, and Yingying Zhang. Meta-analysis of Kangai injection combined with radiotherapy and chemotherapy in the treatment of gynecological malignant tumors. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0063.

Full text
Abstract:
Review question / Objective: This study systematically evaluated the clinical efficacy and safety of Kangai injection combined with radiotherapy and chemotherapy in the treatment of gynecological malignant tumors. The subjects of the study were patients with clinical diagnosis of ovarian cancer, cervical cancer, and endometrial cancer. The experimental group was given Kang'ai injection combined with radiotherapy and chemotherapy, while the control group was given conventional chemotherapy. The primary outcome was the overall clinical response rate. Secondary outcomes included quality of life, body mass, indicators of immune function, and adverse events. Information sources: Eight databases including CNKI, Wan fang Database, VIP Chinese Database, China Biomedical Literature Service System, EI, Springer, PubMed, The Cochrane Library were searched before May 2022.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pregnancy, Cancer, Chemotherapy, Outcome' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography